Literature DB >> 1972346

Hepatic neoplasms in aflatoxin B1-treated, congenital duck hepatitis B virus-infected, and virus-free pekin ducks.

J M Cullen1, P L Marion, G J Sherman, X Hong, J E Newbold.   

Abstract

To assess the effects of the combination of persistent hepadnavirus infection and chemical carcinogen exposure, aflatoxin B1 (AFB) was administered p.o. for 60 days to congenitally duck hepatitis B virus (DHBV)-infected and virus-free Pekin ducks, starting at 3 days of age, during a 28-month study. Hepatic neoplasia occurred only in AFB-dosed ducks. Hepatocellular carcinomas or biliary carcinomas occurred in 4 of 8 DHBV-infected and 3 of 4 DHBV-free ducks, and hepatocellular adenomas developed in 2 DHBV-infected AFB-dosed ducks that survived 20 months or longer. Altered foci of hepatocytes similar to those observed in chemical carcinogen-dosed rodents, characterized by enlarged eosinophilic hepatocytes or vacuolated cytoplasm, occurred in AFB-dosed ducks. Cells in foci or hepatic neoplasms did not contain histochemically detectable gamma-glutamyltranspeptidase but were distinguished from uninvolved parenchyma by altered glycogen content. Immunohistochemical staining indicated that DHBV core antigen persisted in liver, spleen, pancreas, and, to a lesser extent, kidney of most congenitally infected ducks up to 28 months of age. Hepatic neoplasms contained only patches of hepatocytes were detectable viral antigen. Southern blot analysis of restriction endonuclease-digested neoplastic and normal liver DNA revealed high molecular weight forms of DHBV DNA consistent with integration of viral DNA into the genome of hepatic neoplasms from 3 of 4 DHBV-infected ducks but not nontumorous liver. These findings indicate that AFB is a potent hepatic carcinogen in ducks and that persistent congenital DHBV infection did not contribute significantly to the emergence of hepatic neoplasia in ducks under these conditions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972346

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Human hepatitis B virus and hepatocellular carcinoma. II. Experimental induction of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflatoxin B1.

Authors:  R Q Yan; J J Su; D R Huang; Y C Gan; C Yang; G H Huang
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Human hepatitis B virus and hepatocellular carcinoma. I. Experimental infection of tree shrews with hepatitis B virus.

Authors:  R Q Yan; J J Su; D R Huang; Y C Gan; C Yang; G H Huang
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Combined hepatocellular-cholangiocarcinoma in a Yellow-headed Amazon (Amazona oratrix).

Authors:  Anusha Hemamali Tennakoon; Takeshi Izawa; Daisuke Fujita; Yuki Denda; Eiko Seto; Hiroshi Sasai; Mitsuru Kuwamura; Jyoji Yamate
Journal:  J Vet Med Sci       Date:  2013-06-21       Impact factor: 1.267

4.  Hepatic Transcriptome Responses of Domesticated and Wild Turkey Embryos to Aflatoxin B₁.

Authors:  Melissa S Monson; Carol J Cardona; Roger A Coulombe; Kent M Reed
Journal:  Toxins (Basel)       Date:  2016-01-06       Impact factor: 4.546

5.  The isolation and culture of DHBV-infected embryo and duckling hepatocytes and the effect of aflatoxin B1 or irradiation on these cells.

Authors:  I O Olubuyide; D J Judah; J Riley; G E Neal
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

6.  Duck hepatitis B virus infection, aflatoxin B1 and liver cancer in domestic Chinese ducks.

Authors:  L Cova; R Mehrotra; C P Wild; S Chutimataewin; S F Cao; A Duflot; M Prave; S Z Yu; R Montesano; C Trepo
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

Review 7.  Molecular dosimetry of aflatoxin exposure: contribution to understanding the multifactorial etiopathogenesis of primary hepatocellular carcinoma with particular reference to hepatitis B virus.

Authors:  C P Wild; L A Jansen; L Cova; R Montesano
Journal:  Environ Health Perspect       Date:  1993-03       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.